"Waiting for DAAs": A retrospective chart review of patients with untreated hepatitis C in Rwanda.
BACKGROUND:Access to treatment for hepatitis C virus (HCV) in sub-Saharan Africa is extremely limited. With the advent of direct acting antivirals (DAAs), highly effective and easy-to-deliver oral regimens are now available on the global market. This study was conducted to understand the background...
Main Authors: | Neil Gupta, Jules Kabahizi, Constance Mukabatsinda, Timothy David Walker, Emmanuel Musabeyezu, Athanase Kiromera, Jennifer Ilo Van Nuil, Kevin Steiner, Joia Mukherjee, Sabin Nsanzimana, Aimable Mbituyumuremyi |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2017-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5360324?pdf=render |
Similar Items
-
Safety and Efficacy of Limited Laboratory Monitoring for Hepatitis C Treatment: A Blinded Clinical Trial in Rwanda
by: Philip Grant, et al.
Published: (2020-04-01) -
Patient and healthcare provider experiences of hepatitis C treatment with direct-acting antivirals in Rwanda: a qualitative exploration of barriers and facilitators
by: Janvier Serumondo, et al.
Published: (2020-06-01) -
Viral load detection and management on first line ART in rural Rwanda
by: Jean de Dieu Ndagijimana Ntwali, et al.
Published: (2019-01-01) -
Prevalence of hepatitis B and C infection in persons living with HIV enrolled in care in Rwanda
by: Justine Umutesi, et al.
Published: (2017-05-01) -
WAITING DAAS LIST MORTALITY IMPACT IN HCV CIRRHOTIC PATIENTS
by: Giovanni Faria SILVA, et al.